TrialBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Kamal Chamoun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.